Bardoxolone Shows Promise for Polycystic Kidney Disease

16.08.2018

Polycystic kidney disease is a genetic disorder resulting in the development and growth of multiple cysts within the kidney. Polycystic kidney disease has no cure; it is usually treated by reducing the symptoms. The dialisis is the treatment at the end stage of renal failure.

Bardoxolone, an investigational drug, significantly improved kidney function in patients with autosomal dominant polycystic kidney disease.

In a recent study which enrolled 31 patients, investigators found that bardoxolone-treated patients demonstrated a significant mean improvement in estimated glomerular filtration rate.

No drug-related serious adverse events have been reported, and adverse events that have been reported generally have been mild to moderate.

These observations suggest that bardoxolone is addressing pathogenic pathways of inflammation and fibrosis that contribute to the loss of kidney function in patients with chronic kidney disease.

Presentation of the new findings follows the recent FDA approval of tolvaptan for use in adult patients with autosomal dominant polycystic kidney disease.

Reference:

Chin MP, Bakris GL, Block GA, et al. Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study. American Journal of Nephrology. 2018;47(1):40-47. doi:10.1159/000486398.